![Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents](/docs/US/2020-08-18/US10745410B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents
-
Application No.: US16487832Application Date: 2018-05-08
-
Publication No.: US10745410B2Publication Date: 2020-08-18
- Inventor: Hai-Jun Zhang
- Applicant: ZENJI RESEARCH LABORATORIES
- Applicant Address: CN Nanjing
- Assignee: ZENJI RESEARCH LABORATORIES
- Current Assignee: ZENJI RESEARCH LABORATORIES
- Current Assignee Address: CN Nanjing
- Agency: McCarter & English, LLP
- Agent Steven G. Davis; Wei Song
- International Application: PCT/US2018/031474 WO 20180508
- International Announcement: WO2018/217439 WO 20181129
- Main IPC: C07D495/04
- IPC: C07D495/04 ; A61K31/519
![Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents](/abs-image/US/2020/08/18/US10745410B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to novel substituted [5,6]cyclic-4(3H)-pyrimidinone compounds of formula (I) and their preparation methods. (I) In particular, the present invention relates to novel substituted [5,6]cyclic-4(3H)-pyrimidinone compounds useful as inhibitors of protein kinases, specifically CDC7 (cell division cycle 7) inhibitors.
Public/Granted literature
- US20200055867A1 SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS Public/Granted day:2020-02-20
Information query
